Humacyte, Inc. (NASDAQ:HUMA) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC trimmed its holdings in Humacyte, Inc. (NASDAQ:HUMA) by 25.7% in the second quarter, Holdings Channel.com reports. The institutional investor owned 68,319 shares of the company’s stock after selling 23,661 shares during the quarter. Squarepoint Ops LLC’s holdings in Humacyte were worth $328,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of HUMA. nVerses Capital LLC purchased a new position in Humacyte during the second quarter worth about $28,000. China Universal Asset Management Co. Ltd. boosted its stake in Humacyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after buying an additional 7,897 shares during the period. Hartline Investment Corp purchased a new position in Humacyte during the first quarter worth about $70,000. Principal Financial Group Inc. purchased a new position in Humacyte during the second quarter worth about $83,000. Finally, Profund Advisors LLC purchased a new position in Humacyte during the second quarter worth about $97,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 277,090 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the sale, the chief executive officer now owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the transaction, the chief executive officer now owns 4,029,374 shares in the company, valued at $26,070,049.78. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,084,153 shares of company stock worth $6,869,996 in the last 90 days. 11.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

HUMA has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. BTIG Research raised their target price on shares of Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 15th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Finally, Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Humacyte has an average rating of “Buy” and an average target price of $9.80.

Humacyte Trading Up 3.2 %

NASDAQ:HUMA opened at $5.73 on Friday. The company has a market capitalization of $683.88 million, a PE ratio of -4.56 and a beta of 1.45. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte, Inc. has a 52-week low of $1.96 and a 52-week high of $9.97. The stock has a fifty day simple moving average of $6.08 and a 200-day simple moving average of $5.79.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, equities research analysts expect that Humacyte, Inc. will post -1.09 earnings per share for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.